Newsroom

NIAID Now

Showing results filtered by:
Clear All
Vaccines

19 Results

NIAID-Supported Studies Identify Universal Predictors of Antibody Response to Vaccination

January 10, 2023

Two recently published studies explain why some people respond better to vaccines than others and could guide the development of new strategies to enhance the antibody response to vaccination.

hand injects needle of syringe into shoulder muscle

2 NIAID Studies Highlight COVID-19 Nasal Vaccine Potential

December 08, 2022

As scientists learn more about SARS-CoV-2 and its infection tactics, nasal vaccines appear to be a promising response.

SARS-CoV-2 virus particles

NIAID Issues Further Awards to Support Pan-Coronavirus Vaccine Development

December 06, 2022

Developing a vaccine capable of fighting a diverse group of coronaviruses and viral variants remains a priority for NIAID, which NIAID has awarded an additional $26.1 million for four additional “pan-coronavirus” vaccine grant awards,

A scanning electron microscope image showing SARS-CoV-2 virus particles (which appear as spheres) emerging from the surface of a cell cultured in the lab.

NIH Continues Investment in HIV Prevention, Therapy and Cure with $34 Million Award

August 22, 2022

The National Institutes of Health has awarded approximately $34 million annually over the next five years to fund six independent Centers for HIV Structural Biology

Many prescription antiretroviral pills of different colors used to treat HIV infection. Credit: NIAID

NIAID-Funded Adjuvant Improves Typhoid Vaccine Candidate in Animal Studies

August 17, 2022

An investigational typhoid vaccine containing a component developed with NIAID funding may overcome some of the shortcomings of available typhoid vaccines, according to a paper published in the journal Vaccine in June.

S. Typhi shown under a microscope

NIAID Mouse Study Shows Benefits of COVID-19 Nasal Vaccine vs. Intramuscular

June 10, 2022

A new comparison study in PNAS from NIAID intramural scientists clearly shows that for SARS-CoV-2, nasal vaccination – particularly in two doses – has clear advantages over muscular delivery in laboratory mice.

This colorized scanning electron micrograph shows a cell (teal and green) infected with SARS-CoV-2 virus particles (purple and pink) isolated from a patient sample.

NIAID Study Searches for Answers in Mystery of Long COVID

June 07, 2022

NIAID investigators recently published initial results from a study seeking to characterize and better understand persistent symptoms some people experience after having COVID. These persistent symptoms, often referred to as “long COVID,” can sometimes be debilitating, and their cause is currently unknown. This single-site study is part of a larger research effort across multiple institutes at NIH and NIH-funded institutions to understand, prevent, and treat long-term health effects related to COVID-19.

Colorized scanning electron micrograph of an apoptotic cell (tan) heavily infected with SARS-COV-2 virus particles (orange).

How Children are Helping Scientists Battle a ‘List of Bad Viruses’

May 19, 2022

The national EV-D68 pilot study is part of PREMISE, the Pandemic Response Repository through Microbial and Immune Surveillance and Epidemiology. PREMISE is an initiative from NIAID’S Vaccine Research Center (VRC) that began in early 2021.

CDC poster showing how to prevent getting and spreading EV-D68

NIAID Observes HIV Vaccine Awareness Day 2022

May 18, 2022

Today marks the 25th anniversary of the first HIV Vaccine Awareness Day. Although tremendous progress has been made over the past several decades in HIV treatment and prevention, the development of a safe, effective, and durably protective vaccine to prevent HIV infection has, unfortunately, remained elusive. On this commemorative day, NIAID acknowledges the disappointments of the past while optimistically looking ahead to what’s next in HIV vaccine development. 

A Syringe, a Vaccine Bottle, and glass Globe

NIH’s Dr. Carl Dieffenbach Discusses Highlights of HIV Cure, Treatment and Prevention Research from CROI 2022

February 18, 2022

In an HIV.gov video conversation on February 16, NIAID's Dr. Carl Dieffenbach discussed some of the pivotal HIV research advances presented this week at the 2022 virtual Conference on Retroviruses and Opportunistic Infections (CROI 2022). Dr. Dieffenbach, who directs the Division of AIDS, covered developments in HIV cure, treatment and prevention research. Watch the conversation and read summaries of the study findings he discussed.

Head shot of Dr. Carl Dieffenbach, director of the NIAID Division of AIDS

NIAID Observes HIV Vaccine Awareness Day 2021

May 18, 2021

While implementation of highly effective HIV treatment and prevention tools has reduced the HIV pandemic worldwide, development of a safe and even modestly effective vaccine would hasten progress toward a durable end of the HIV pandemic. Today, on HIV Vaccine Awareness Day, NIAID acknowledges both the progress that has been made in HIV vaccine development and the challenges that remain. We also reflect on how advances in HIV vaccinology paved the way for COVID-19 vaccine development.

Clinician holds syringe with experimental vaccine

Single-Dose COVID-19 Nasal Vaccine Limits Infection in Monkeys

April 01, 2021

Single-dose experimental COVID-19 vaccine delivered into the nose of rhesus macaques protected lungs and nasal regions from SARS-CoV-2 infection.

SARS-CoV-2, the virus that causes COVID-19.

Vaccine to Protect Broadly Against Mosquito-Borne Diseases Appears Safe in Early Trial

June 12, 2020

A vaccine developed to protect broadly against Mosquito-borne diseases appears safe in Phase 1 of a NIAID trial.

Aedes mosquitoes

NIAID Observes HIV Vaccine Awareness Day 2020

May 17, 2020

A safe and effective HIV vaccine remains elusive. On HIV Vaccine Awareness Day 2020, NIAID honors researchers and clinical study participants.

A researcher prepares to administer an investigational vaccine to a clinical trial participant.

Experimental Chikungunya Vaccine is Safe and Well-Tolerated in Early Trial

April 17, 2020

A NIAID-led trial has proven an experimental chikungunya vaccine to be both safe and to confer durable immune responses in healthy volunteers.

Photo of Aedes mosquito

Prickly Patch Delivery of Experimental COVID-19 Vaccine Shows Promise in Animal Study

April 03, 2020

A candidate vaccine delivered though a thumbnail-sized patch studded with microneedles could help address the coronavirus disease 2019 (COVID-19) pandemic.

microneedle patch vaccine

NIAID Acknowledges World Tuberculosis Day

March 24, 2020

NIAID reiterates commitment to researching tuberculosis, the world’s leading cause of death from a single infectious disease.

A scanning electron micrograph of Mycobacterium tuberculosis, the bacteria which causes tuberculosis.

Promising Results in Trial of Universal Flu Vaccine Candidate

March 16, 2020

An efficacy trial of an experimental vaccine to protect against many flu virus strains has yielded promising results.

Flu virus particles

Ready, Set, Go—Immune System Status Predicts Future Responses

February 24, 2020

Identifying predictors of autoimmune disease flare-ups could aid treatment for these conditions by allowing doctors to intervene before symptoms worsen. Recognizing immune system attributes that forecast a healthy person’s response to vaccination or infection would help researchers develop new vaccines. A new NIAID study connects these seemingly distinct avenues of research.

Top row of graphic labeled "High responder" shows a panel (left) of intensely colored cartoon immune cells producing many chemicals and a panel (right) depicting a robust immune response after a vaccine or disease flare. Bottom “low responder” row show a panel (left) of weakly colored cartoon immune cells producing few chemicals and a panel (right) depicting a weak immune response.

Contact

Contact the NIAID Media Team.
301-402-1663

niaidnews@niaid.nih.gov

Stay Connected

Subscribe to NIAID Now email updates